Targeting of PCSK9 with siRNA for LDL-C Reduction in a High-Risk Population

Released On
October 1, 2019

Expires On
October 1, 2020

Media Type

Completion Time
85 minutes

Cardiology, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by The National Lipid Association.


Supported by an educational grant from The Medicines Company.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)
  • Pharmacists — 1.25 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the needs of lipidologists, internists, endocrinologists, with an interest in developing a core competency in the diagnosis and treatment of dyslipidemia and management of ASCVD and cardiovascular risk.

Program Overview

Heart disease is the leading cause of death for both men and women in the United States, with 610,000 people dying of this disease every year – or 1 in every 4 deaths. Elevated LDL-C is a major risk factor for heart disease. Although there have been consistent educational efforts that focus on lowering LDL-C levels, and the use of statins has progressively increased, there remain significant gaps in overall lipid control. Risk for cardiovascular events persists in patients who may be receiving optimal/maximally tolerated statin treatment. In light of emerging therapies and upcoming cardiovascular outcomes trials (CVOTs), these patients may be able to further reduce their risk in primary and secondary prevention with the appropriate use of non-statin therapies. In order to bring further insight to this evolving landscape of cardiovascular risk management, the NLA presented a supplementary 75-minute symposium during the European Society of Cardiology 2019 Annual Congress on August 31 in Paris, France. Watch the proceedings and claim your credit today!

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the role of non-statin therapies in cardiovascular risk management
  • Identify proposed methods to improve patient outcomes through overcoming poor adherence and other management barriers
  • Assess the implications of ongoing clinical trials for the management of cardiovascular risk
  • Summarize the mechanism of action, efficacy, and safety of novel agents for LDL-C and ASCVD risk reduction


Christie M. Ballantyne, MD, FNLA

Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Houston, TX

Harold E. Bays, MD, FTOS, FACC, FACE, FNLA

Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Pamela B. Morris, MD, FNLA - Moderator and Reviewer

Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Mt. Pleasant, SC

Joseph J. Saseen, PharmD, CLS, FNLA

Professor and Vice Chair
University of Colorado
Anschutz Medical Campus
Aurora, CO

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

The National Lipid Association designates this enduring internet activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants Credit Designation

NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Pharmacists Continuing Education Credit Designation

This Activity has been approved for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA0007192-0000-19-049-H01-P (Application)

Disclosures of Conflicts of Interest

Christie M. Ballantyne, MD, FNLA

  • Contracted Research: Abbott Diagnostics, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
  • Consultant: Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo

Harold E. Bays, MD, FTOS, FACC, FACE, FNLA

  • Contracted Research: Acasti, Akcea, Alera, Allergan, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Dr. Reddy, Eisai, Eli Lily, Esperion, Evidera, Gan & Lee, Gemphire, GlaxoSmithKline, Home Access, iSpecimen, Janssen, Johnson & Johnson, LIB, MedImmune, Merck, Metavant, Nektar, Novartis, Novo Nordisk, Omthera, Pfizer, Qualigen, Regeneron, Sanofi, Selecta, Takeda, TIMI, The Medicines Company, Urovant
  • Consultant: Aegerion, Alnylam, Amarin, Amgen, AstraZeneca, Esperion, Gemphire, Ionis, Janssen, Johnson & Johnson, Kowa, Merck, Metinas, Novartis, Prosciento, Regeneron, Sanofi, Takeda
  • Speaker: Amarin, Amgen, Kowa, Regeneron, Sanofi

Pamela B. Morris, MD, FNLA - Moderator and Reviewer

  • Advisory Board: Amgen, Sanofi-Regeneron
  • Contracted Research: Esperion

Joseph J. Saseen, PharmD, CLS, FNLAh Has nothing to disclose

Staff/Reviewer Disclosures

NLA staff has nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

Participation in this activity is free. Understand the material, pass the intra-activity questions and complete an evaluation to receive credit. Passing grade is 70% and you are limited to 3 attempts.There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form to The National Lipid Association.

For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

For CME questions, please contact: The National Lipid Association at: